As researchers pour resources into finding drugs to treat COVID-19, the company has started offering free toxicity screening on potential treatments for the virus.

The 2-year-old company also announced it has closed a $2.5 million seed round, with Primary Venture Partners and Meridian Street Capital as lead investors.

“Our tools try to figure out what’s going on with the drug,” Madhukar said.

Madhukar points to prior work with cancer drug developer Oncoceutics in which OneThree Biotech helped identify a type of cancer not previously on researchers’ radar as a strong potential candidate for a treatment.

The seed funding will be used to build out the platform’s back-end infrastructure and to pursue partnerships with biotech and pharma researchers. | To read full story, visit https://startuparound.com/read/1585233005.9275324/OneThree-Biotech-Raises-Seed-Round-For-AI-Driven-Drug-Platform?ref=audio_experience